The authors thank the VPA Clinical Trial investigators for their contributions to the design, execution, and management of the VPA Trial. The VPA Clinical Trial investigators are: Paul S. Bernstein, MD, PhD; David G. Birch, PhD; Judith Chiostri, MS; Laura R. Erker, PhD; John R. Heckenlively, MD; Alessandro Iannaccone, MD, MS; Byron L. Lam, MD; Jennifer B. McCormack, MS; Mark E. Pennesi, MD, PhD; and David J. Wilson, MD.
Supported by grant P30 EY010572 from the National Institutes of Health (Bethesda, MD) and by unrestricted departmental funding from Research to Prevent Blindness (New York, NY). The VPA Clinical Trial was co-sponsored by the Foundation Fighting Blindness Clinical Research Institute and the Department of Defense (W81XWH-09-2-0189).
Disclosure: T.B. Smith, Applied Genetic Technologies Corporation (C); M.A. Parker, None; P.N. Steinkamp, None; A. Romo, None; L.R. Erker, None; B.J. Lujan, Genentech/Roche (C), BioTime/Cell Cure (C), Carl Zeiss Meditec (R) P; N. Smith, None